Literature DB >> 25032133

Bilateral laparoscopic gonadectomy in a patient with complete androgen insensitivity syndrome and bilateral sertoli-leydig cell tumor: a case report and brief review of the literature.

Mohammad Asl Zare1, Mahmood Reza Kalantari2, Amir Abbas Asadpour1, Ali Kamalati3.   

Abstract

INTRODUCTION: Complete androgen insensitivity syndrome (previously called testicular feminization) is specified by a 46 XY karyotype and negative sex chromatin, bilateral undescended testes, female genitalia appearance, and lack of mullerian derivatives. CASE
PRESENTATION: A 28-year-old woman with complete (severe) androgen resistance underwent prophylactic laparoscopic bilateral gonadectomy because of the eventually increased risk of gonadal malignancy. Although the gonads appeared grossly normal, microscopic examination revealed bilateral well differentiated sertoli-leydig cell tumor (SLCT). DISCUSSION: Our Medline search revealed that this is the first reported case of bilateral sertoli-leydig cell tumor (SLCT) in androgen insensitivity syndrome.

Entities:  

Keywords:  Androgen-Insensitivity Syndrome; Laparoscopy; Sertoli-Leydig Cell Tumor

Year:  2014        PMID: 25032133      PMCID: PMC4090667          DOI: 10.5812/numonthly.15278

Source DB:  PubMed          Journal:  Nephrourol Mon        ISSN: 2251-7006


1. Introduction

Complete androgen insensitivity syndrome (AIS - previously called testicular feminization) is specified by a 46 XY karyotype and negative sex chromatin, bilateral undescended testes, female genitalia appearance, and lack of mullerian derivatives. The patient is phenotypically female without uterus and a blind shortened vagina (1). This syndrome is often diagnosed during puberty while the patient is being evaluated due to primary amenorrhea (2). Complete AIS is accompanied with abnormal testicular development and increase risk of germ cell malignancy beginning after puberty. For these reason, prophylactic gonadectomy is advised in the postpubertal period to avoid potential malignant transformation (2). We present the first documented case of bilateral sertoli–leydig cell tumor (SLCT) in a patient with complete (severe) AIS.

2. Case Presentation

A 28-year-old nulligravida was referred for consultation and laparoscopic bilateral gonadectomy after diagnosis of complete androgen resistance. The patient complained of primary amenorrhea but she did not have inguinal hernia or labial mass. She had female external genitalia. In the physical examination, development of her breasts was normal (tanner stage IV), but axillary hair was scarce (tanner stage III). Abdominal examination was normal. No inguinal or labial mass was palpated. In gynaecological examination, the vulva and perineum appeared normal. She had a blind-ending vaginal pouch of approximately 6 cm depth and the cervix was invisible. No adnexal masses were palpated. In pelvic ultrasonography, the uterus was absent and an ovoid heterogenous mass (38 × 23 mm in size) with a 13 mm nodule in the right pelvic sidewall had been reported. Abdominal ultrasonography did not reveal any para-aortic lymphadenopathy. Pelvic ultrasonography failed to identify the left gonad. Blood tests for hormones showed Follicle-stimulating hormone and luteinizing hormone levels were 7 mIU/mL and 32 mIU/mL, respectively and serum testosterone was 3.1 ng/mL, all of which were within the normal ranges. Cytogenetic analysis showed a male karyotype (46, XY). The patient underwent laparoscopic gonadectomy under general anesthesia in the supine position. Visualization of pelvic contents revealed absence of uterus and fallopian tubes. There was not any evidence of abdominal or pelvic lymphadenopathy. Laparoscopic study demonstrated a 4 × 2.5 cm gray-purple colored ovoid mass with 1 cm cystic mass near the right internal inguinal ring. The left gonad (4.5 × 2 cm) was hidden behind the bowels in the left pelvic sidewall. The gonad and the attached structure were retracted medially. The posterior peritoneum and gonadal vessels were incised after coagulation and ligation, and the gonads were removed from the pelvic sidewalls (Figure 1).
Figure 1.

A. Laparoscopic View of the Left Gonad; B. The Right Gonad; C. Gross Image of the Removed Gonads

Macroscopically, the specimen consist of two ovoid gray mass which one of them contained two well-delineated, homogenous yellow-tan nodules measuring 1.5 and 1 cm on cut surface, respectively. Another mass on cut surface contained one 2.3 cm nodule similar to above description. Histopathological examination of the gonads in non-neoplastic region showed prepubertal immature tubules with lined sertoli cells. Microscopic examination of delineated nodules revealed a luminal-tubular pattern populated by monomorphus cells with dark round to oval nuclei reminiscence of immature sertoli cells. Intervening stroma was scant and focally contained clusters of polygonal cells with abundant eosinophilic or vacuolated cytoplasm and round nucleus with prominent nucleoli. Mitotic activity was not prominent and necrosis was not seen (Figure 2). These findings were consistent with bilateral well differentiated sertoli–leydig cell tumor (SLCT). Our patient is being followed up regularly and she has no complain after a year.
Figure 2.

Well-differentiated Sertoli-Leydig Cell Tumor: A. The Tumor Is Well Circumscribed; B. Tumor Growth in Aluminal Tubular Pattern; C. Tumoral Cells Reveal Dark Round to Oval Nuclei and Clear Cytoplasm; D. Inervening Stroma Contain of Large Polygonal Cells Reminiscence to Leydig Cells.

3. Discussion

AIS is the most common type of male pseudohermafroditism characterized by absence of androgen receptor (AR) activity due to a mutation at Xq11–q12 localization on the androgen receptor gene (3-5). It is known as an X-linked recessive disease, but up to 30% of mutations may be presented as sporadic de novo mutations (6). The incidence of this condition is 1 in 99,000 to 1 in 20,000 female births (7-9). These patients may be seen with a spectrum of phenotypic disorders that varies from pure female complete androgen insensitivity syndrome (CAIS), ambiguous genitalia partial androgen insensitivity (PAIS) and to phenotypically infertile male minimal androgen insensitivity form (MAIS) (2). The complete form is 10 times more common than the incomplete form and the initial presentation is primary amenorrhea in adolescents with female phenotype, lack of pubic hair, or inguinal hernia containing testis and characterized by a 46 XY genotype and normal male androgen and gonadotropin value. Pelvic ultrasonography usually shows absence of mullerian derivates and vaginal examination reveals a blind-ending vagina without a cervix. Notably, on physical examination, all of these characteristics were present in our patient (2). In children or infants with a female phenotype, androgen insensitivity syndrome may present as inguinal hernia or mass and ambiguous genitalia. About 50% of patients with complete (severe) AIS have an inguinal hernia. Conversely, 1-2% of apparently female infants with inguinal hernia are diagnosed to have a 46 XY karyotype and complete AIS. It may be found during workup for lower abdominal pain (10), abdominal mass (11), painful intercourse, or diagnosed incidentally on imaging investigations (12). The testes may be found in the abdomen, inguinal canal, or labia. Abnormalities of testicular development and risk of gonad malignancy increase after puberty. Testis tumor developing risk is thought to be 3.6% by 25 years and 33% by 50 years (11, 13). In a case series of 43 patients with AIS by Rutgers and Scully, 63% hamartomas, 23% sertoli cell adenomas and 9% malignant tumors including two seminomas, one intratubular germ cell neoplasm with early stromal invasion and a malignant sex cord tumor were reported (13). We reviewed the previous articles on gonadal tumors in CAIS patients (Table 1). Most cases are unilateral sertoli adenoma or tumor. There are only two reported cases of bilateral gonadal tumors (10, 14). Also, there are only two cases of sertoli-leydig cell tumor which both were unilateral (15, 16).
Table 1.

Reported Cases of Sex Cord Stromal Tumors in Patients With Complete Androgen Insensitivity Syndrome

Tumor TypeAge, yTumor Size, cmLocalizationReference
Sertoli cell adenoma 217.5 × 3right gonadO’Connell et al. (17)
Sertoli cell adenoma 8224 × 19left gonadDamjanow et al. (18)
Sertoli cell adenoma 205 × 2.5left gonadRamaswamy et al. (19)
Sertoli cell adenoma (10 cases) 17-530.5 to 14left gonadRutgers and Scully (13)
Large cell calcifying sertoli cell tumor / sex cord tumor with annular tubules (2 caces) 18 and 201 to 8left gonadRutgers and Scully (13)
Sertoli cell tumor 2626 × 17bilateralWysocka et al. (14)
Sertoli cell adenoma 222left gonadKo et al. (20)
Sertoli cell tumor and adenocarcinoma of tunica vaginalis testis 7235 × 25Fleckenstein et al. (21)
Sertoli cell adenoma and serous cyst 30bilateralBaksu et al. (10)
Malignant leydig cell tumor 7310.5 × 9.5left gonadIwamoto et al. (11)
Sertoli-leydig cell tumor and ureteral transitional cell carcinoma 572 × 1.8right gonadChoi et al. (22)
Sertoli cell adenoma 5314 × 10 × 10left gonadScully et al. (23)
Sertoli cell tumor 60large abdominal tumorKnoke et al. (24)
Sertoli cell adenoma 6715 × 14 × 10left gonadLentz et al. (25)
Sertoli cell adenoma 8116 × 11 × 6left gonadDetre and Bujdoso (26)
Large cell calcifying sertoli cell tumor/sex cord tumor with annular tubules (2 cases) 198 × 8 × 4.5right gonadRamaswamy et al. (19)
Sertoli-leydig cell tumor Jarzabec et al. (15)
Sertoli-Leydig cell tumor 29left gonadOzulker et al. (16)
Sertoli cell tumor and ITGCN 15separate gonadsLin et al. (27)
Sertoli-leydig cell tumor 284 × 2.5Bilateralpresent case
In AIS pateints, prophylactic gonadectomy is advised in the postpubertal period due to avoid potential malignant transformation of the gonads (2, 28). Gonadectomy is recommended during the postpubertal period to help the development of feminization during puberty when the malignant changes in germ cells are relatively late and rare (13). Sertoli-leydig cell tumor is a rare sex cord stromal neoplasm that account for less than 1% of ovarian tumors, occurring often in young adults (29, 30). It is also seldom developed among the patients with AIS and there is only two unilateral cases reported in the literature (15, 16). According to the amount of tubular differentiation of the sertoli cells and quantity of the primitive gonadal stroma, sertoli-leydig cell tumor is divided into well, intermediate and poorly differentiated types. Our patient had a well-differentiated form of SLCT, which is the most infrequently type seen with the good prognosis. To our knowledge, this is the first documented case report of bilateral benign sertoli-leydig cell tumor (SLCT) in androgen insensitivity syndrome.
  28 in total

1.  The syndrome of testicular feminization in male pseudohermaphrodites.

Authors:  J M MORRIS
Journal:  Am J Obstet Gynecol       Date:  1953-06       Impact factor: 8.661

2.  Male pseudohermaphroditism proved by surgical exploration and microscopic examination; a case report with speculations concerning pathogenesis.

Authors:  M B GOLDBERG; A F MAXWELL
Journal:  J Clin Endocrinol Metab       Date:  1948-05       Impact factor: 5.958

3.  Giant sertoli cell adenoma in testicular feminization syndrome.

Authors:  I Damjanov; K A Nesbitt; M P Reardon; R A Vidone
Journal:  Obstet Gynecol       Date:  1976-11       Impact factor: 7.661

4.  Testicular feminization syndrome in three sibs: emphasis on gonadal neoplasia.

Authors:  M J Connell; H E Ramsey; J Whang-Peng; P H Wiernik
Journal:  Am J Med Sci       Date:  1973-04       Impact factor: 2.378

5.  Androgen receptor gene mutation associated with complete androgen insensitivity syndrome and Sertoli cell adenoma.

Authors:  H M Ko; J H Chung; J H Lee; I S Jung; I S Choi; S W Juhng; C Choi
Journal:  Int J Gynecol Pathol       Date:  2001-04       Impact factor: 2.762

6.  Simultaneous sertoli cell tumor and adenocarcinoma of the tunica vaginalis testis in a patient with testicular feminization.

Authors:  Georg H Fleckenstein; Bastian Gunawan; Ulrich Brinck; Wolfgang Wuttke; Günter Emons
Journal:  Gynecol Oncol       Date:  2002-03       Impact factor: 5.482

7.  A testicular tumor resembling the sex cord with annular tubules in a case of the androgen insensitivity syndrome.

Authors:  G Ramaswamy; V Jagadha; V Tchertkoff
Journal:  Cancer       Date:  1985-04-01       Impact factor: 6.860

Review 8.  Postmenopausal diagnosis of testicular feminization.

Authors:  S S Lentz; J O Cappellari
Journal:  Am J Obstet Gynecol       Date:  1998-07       Impact factor: 8.661

Review 9.  Androgen insensitivity syndrome: clinical features and molecular defects.

Authors:  Angeliki Galani; Sophia Kitsiou-Tzeli; Christalena Sofokleous; Emmanuel Kanavakis; Ariadni Kalpini-Mavrou
Journal:  Hormones (Athens)       Date:  2008 Jul-Sep       Impact factor: 2.885

10.  Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.

Authors:  Katarzyna Jarzabek; Pascal Philibert; Mariusz Koda; Stanislaw Sulkowski; Malgorzata Kotula-Balak; Barbara Bilinska; Marie-Laure Kottler; Slawomir Wolczynski; Charles Sultan
Journal:  Gynecol Endocrinol       Date:  2007-09       Impact factor: 2.260

View more
  3 in total

1.  Laparoscopic Gonadectomy and Hernia Repair for Complete Androgen Insensitivity Syndrome (CAIS): A Rare Cause of Primary Amenorrhea.

Authors:  Priyata Lal; Urvashi Jha; Ramandeep Kaur; Neema Sharma; Ritambhara Agarwal; Randeep Wadhawan
Journal:  J Obstet Gynaecol India       Date:  2015-06-11

2.  Testicular Feminization or Androgen Insensitivity Syndrome (AIS) in Iran: a Retrospective Analysis of 30-Year Data.

Authors:  Dariush D Farhud; Marjan Zarif Yeganeh; Hosein Sadighi; Shahram Zandvakili
Journal:  Iran J Public Health       Date:  2016-01       Impact factor: 1.429

Review 3.  [Complete androgen insensitivity syndrome: report of two cases and review of literature].

Authors:  Boutaina Lachiri; Ihssane Hakimi; Adil Boudhas; Khalid Guelzim; Jaouad Kouach; Mohamed Oukabli; Driss Moussaoui Rahali; Mohamed Dehayni
Journal:  Pan Afr Med J       Date:  2015-04-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.